Holen Sie sich die Stockscreener-App
427.50
2.13%
-9.29
Handel nachbörslich:
429.98
2.48
+0.58%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$436.79
Offen:
$434.54
24-Stunden-Volumen:
3.04M
Relative Volume:
1.49
Marktkapitalisierung:
$169.62B
Einnahmen:
$42.88B
Nettoeinkommen (Verlust:
$6.34B
KGV:
25.86
EPS:
16.53
Netto-Cashflow:
$7.27B
1W Leistung:
+0.01%
1M Leistung:
-17.72%
6M Leistung:
-28.66%
1J Leistung:
-21.88%
1-Tages-Spanne:
$425.05
$436.02
1-Wochen-Bereich:
$420.00
$450.84
52-Wochen-Spanne:
$409.85
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Is Thermo Fisher Scientific Inc. (TMO) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
Drug Abuse Testing Market Forecast Report and Company - GlobeNewswire
NMR Spectroscopy Market to Hit USD 2.08 Billion by 2032, Fueled by Pharmaceutical R&D and Rising Demand for Molecular Structure Analysis | SNS Insider - GlobeNewswire Inc.
Biochips Market Set to Witness Significant Growth by 2023 | - openPR.com
Thermo Fisher opens collaboration centre in US to help accelerate cell therapy development - BioSpectrum Asia
Assessing Thermo Fisher Scientific: Insights From 9 Financial Analysts - Benzinga
Thermo Fisher swaps HFCs for natural refrigerants in new large‑capacity and superspeed centrifuges - R&D World
Thermo Fisher Scientific Inc. (TMO): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Theranostics Market Growth Analysis and Forecast 2025-2032 | - openPR.com
Leerink Adjusts Price Target on Thermo Fisher Scientific to $625 From $640, Maintains Outperform Rating - MarketScreener
Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development - Bakersfield.com
Lobbying Update: $1,450,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Nasdaq
Thermo Fisher Scientific named founding sponsor of LifeSciNKY - LINK nky
10 manufacturing acquisitions to know from Q1 - Manufacturing Dive
Bernstein Cuts Price Target on Thermo Fisher Scientific to $585 From $690, Keeps Outperform Rating - MarketScreener
Baird Cuts Price Target on Thermo Fisher Scientific to $603 From $660, Keeps Outperform Rating - MarketScreener
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Next Generation Sequencing Market on the Rise: Applications & - openPR.com
Thermo Fisher stock gains after Sartorius Q1 results (TMO) - Seeking Alpha
Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings - TradingView
Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor - Technology Networks
Northern Kentucky-based LifeSciKY announces Thermo Fisher Scientific as founding sponsor - Northern Kentucky Tribune
Thermo Fisher Scientific - WACH
LifeSciKY inks partnership with Thermo Fisher Scientific as Founding Sponsor - Yahoo Finance
Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster - MSN
Thermo Fisher acquires Solventum’s PF business in $4.1bn deal - Financier Worldwide
Thermo Fisher Scientific Stock Up 1.3% After Key Signal - Benzinga
Sickle Cell Anemia Testing and Screening Market Detailed In New - openPR.com
Thermo Fisher Scientific launches bench scale bioreactor enabling productivity, scalability and efficiency - BioSpectrum Asia
3d Cell Culture Market Set to Witness Significant Growth - openPR.com
Thermo Fisher Scientific (NYSE:TMO) Launches 5L DynaDrive Bioreactor To Enhance Bioprocessing - simplywall.st
Thermo Fisher Scientific And Its Real Value (NYSE:TMO) - Seeking Alpha
BofA Securities Cuts Price Target on Thermo Fisher Scientific to $545 From $680, Keeps Buy Rating - MarketScreener
Helicobacter Pylori Diagnostics Market Is Booming Worldwide | Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc. - openPR.com
Thermo Fisher Scientific Introduces 5L DynaDrive Single-Use Bioreactor - Contract Pharma
SPONSORED Boys & Girls Clubs and Thermo Fisher Scientific fuel the future of STEM - Axios
Why Thermo Fisher Scientific (TMO) Is One of the Best Medical Stocks to Buy According to Billionaires - Insider Monkey
Bernstein maintains Thermo Fisher stock with $690 target - Investing.com
Ultrasonic Aspirator Market Poised for Rapid Growth, Expected - openPR.com
Nucleic Acid Isolation And Purification Market Generated - openPR.com
Thermo Fisher Scientific Inc (TMO) Trading Down 6.22% on Apr 10 - GuruFocus
Meningitis Diagnostic Testing Market Deep Research Report with - openPR.com
The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri - Yahoo Finance
Escherichia Coli Strain Market to Witness Remarkable Growth - openPR.com
Nanorobotics Market Set to Witness Significant Growth - openPR.com
Top Research Reports for Eli Lilly, American Express & Thermo Fisher - Yahoo Finance
Barclays Adjusts Price Target on Thermo Fisher Scientific to $475 From $620 - MarketScreener
Assisted Reproductive Technology Market Forecast Report and Company Analysis 2025-2033 Featuring Thermo Fisher Scientific, Sumitomo Mitsui, CooperSurgical, Fujifilm, Merck, Progyny, Cosmos BiomedicalResearchAndMarkets.com - Bluefield Daily Telegraph
gRNA Market Top Companies StudyThermo Fisher Scientific Inc., - openPR.com
Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
2.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):